CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Cyclin-dependent kinase-2 (CDK2) inhibitors are established cancer therapies targeting cell proliferation, apoptosis, and differentiation.
• The precise mechanisms by which CDK2 inhibitors impact the tumor microenvironment remain incompletely understood.

Purpose of the Study:

• To investigate the role of CDK2 inhibition in modulating antitumor immunity.
• To elucidate the molecular mechanisms underlying CDK2 inhibition-induced immune responses.

Main Methods:

• Utilized murine models of fibrosarcoma and lung carcinoma.
• Employed small molecular inhibitors and genetic deficiency to inhibit CDK2.
• Analyzed RB protein phosphorylation, DNMT1 transcription, endogenous retroviral RNA expression, and type I interferon (IFN-I) response.
• Assessed tumor antigen presentation and CD8+ T-cell infiltration.

Main Results:

• CDK2 inhibition, via small molecules or genetic means, promoted antitumor immunity in preclinical cancer models.
• CDK2 inhibition led to reduced RB phosphorylation and E2F-mediated DNMT1 transcription.
• This resulted in increased endogenous retroviral RNA expression and a heightened type I interferon (IFN-I) response.
• The enhanced IFN-I response improved tumor antigen presentation and boosted CD8+ T-cell infiltration into tumors.

Conclusions:

• CDK2 inhibition in cancer cells suppresses tumor growth by enhancing antitumor immune responses.
• This occurs through a mechanism involving increased type I interferon signaling, improved antigen presentation, and augmented CD8+ T-cell activity.
• CDK2 inhibitors represent a potential strategy to bolster anti-cancer immunity within the tumor microenvironment.